<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02874768</url>
  </required_header>
  <id_info>
    <org_study_id>201605038MINB</org_study_id>
    <nct_id>NCT02874768</nct_id>
  </id_info>
  <brief_title>Comparison Between Dexmedetomidine and Propofol for Patients in the Intensive Care Unit After Abdominal Surgery</brief_title>
  <official_title>Comparison Between Dexmedetomidine and Propofol for Postoperative Sedation of Patients in the Intensive Care Unit After Abdominal Surgery: Microcirculation, Kidney Injury, and Intestinal Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-blind randomized clinical trial. Patients undergoing abdominal surgery will
      be enrolled and randomly divided into two groups: dexmedetomidine group and propofol group.
      In the dexmedetomidine group, patients will receive continuous intravenous infusion of
      dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h). In the propofol group, patients
      will receive continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6
      mg/kg/h). Hemodynamics will be continuously monitored using a non-invasive monitoring with
      chest bioreactance technique at preset time points (0, 2, 4, 6, 12h and 24h). Clinical data
      such as vital signs, hemodynamic parameters, laboratory results and fluid balance will be
      recorded. The microcirculation will be examined by Cytocam. The following microcirculatory
      parameters will be investigated: total small vessel density, perfused small vessel density,
      microvascular flow index, and heterogeneity index. The enzyme-linked immunosorbent assays
      will be used to measure serum level of endocan, diamine oxidase, and neutrophil
      gelatinase-associated lipocalin at preset time points. The primary goal of this study is to
      compare the effect on microcirculation between dexmedetomidine and propofol in intensive care
      unit patients after abdominal surgery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total perfused small vessel density</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Microcirculation</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6 mg/kg/h)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h)</description>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6 mg/kg/h)</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Fresofol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-emergent major abdominal surgery with ICU admission

          -  the need of sedation during ICU stay

        Exclusion Criteria:

          -  age younger than 20 years and older than 89 years

          -  refractory bradycardia (HR &lt; 60 bpm after treatment)

          -  severe AV block (2nd or 3rd degree)

          -  refractory shock (MAP &lt; 60 mm Hg after treatment)

          -  severe heart failure or NYHA 4

          -  new onset of myocardial infarction within 4 weeks

          -  receive CPR within 4 weeks

          -  APACHE score &gt; 30 before enrollment

          -  severe liver cirrhosis or CHILD B or C

          -  pregnancy

          -  allergic history to dexmedetomidine or propofol

          -  be enrolled in other clinical trials related to dexmedetomidine or propofol within 4
             weeks

          -  non-native speakers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Chang Yeh, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-Chang Yeh, PhD</last_name>
    <phone>886-9-10513711</phone>
    <email>tonyyeh@ntuh.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu-Chang Yeh, PhD</last_name>
      <phone>886-9-10513711</phone>
      <email>tonyyeh@ntuh.gov.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2016</study_first_submitted>
  <study_first_submitted_qc>August 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2016</study_first_posted>
  <last_update_submitted>August 19, 2016</last_update_submitted>
  <last_update_submitted_qc>August 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

